Inositol and folates in the restoration of reproductive function in women and prevention of congenital malformations

Literature review




reproductive function, congenital malformations, prevention, myo-inositol, metafolin


In recent years, Ukraine has seen a significant deterioration in the reproductive health of women in the face of declining birth rates. One of the main causes of comorbidity of infertility and background pathologies is the insufficient supply of a woman's body in the pre-pregnancy period with micronutrients – folate, vitamins, myo-inositol and others. This increases the risk of complications during pregnancy and childbirth and congenital malformations.
Literature analysis showed that myo-inositol in combination with folate are an extremely important way to prevent fertility disorders, complications of pregnancy and childbirth, congenital malformations and support the reproductive health of the next generation. Myo-inositol in combination with folic acid promotes the effects of luteinizing and follicle-stimulating hormones, normalization of ovarian function, oocyte quality, trophoblast invasion during blastocyst attachment, prevention of congenital malformations by neutralizing the action of homocysteine with metafolin in the pregravid period and during pregnancy and assisted reproductive technologies, reducing the incidence of miscarriage, preeclampsia and other complications. The neuroprotective effect of myo-inositol indicates the importance of its use for fetal neuroprotection in late gestation, especially in hypoxia.
Fertifolin, which contains an improved combination of natural nutrients as myo-inositol 1000 mg and folic acid 100 µg in the form of metafolin (calcium L-methylfolate), successfully copes with this goal. Metafolin has greater bioavailability and more actively helps to increase the level of folate in blood plasma, in contrast to folic acid. Metafolin is characterized by fewer drug interactions and less often masks the symptoms of B12-deficient anemia, reduces the risk of anemia, placental dysfunction, malformations of the neural tube. Fertifolin is also effectively used as an adjunct in polycystic ovary syndrome and in assisted reproductive technology protocols.

Author Biographies

H.I. Reznichenko, Zaporizhzhia Medical Academy of Postgraduate Education of the MoH of Ukraine, Zaporizhzhia

MD, professor, Department of Obstetrics and Gynecology

Y.H. Reznichenko, Zaporizhzhia State Medical University, Zaporizhzhia

MD, professor, Department of Hospital Pediatrics


  1. Veropotvelian, P.N., Tsekhmistrenko, I.S., Veropotvelian, N.P. “Modern approach to the preservation of reproductive potential.” Women's health 9 (2015): 94–7.
  2. Gromova, O.A., Torshin, I.Y., Kalacheva, A.G., Tetruashvili, N.K. “Roles of myoinositol in female reproductive health. Improving the efficiency of in vitro fertilization technologie.” Russian Journal of Woman and Child Health 1 (2018): 88–95.
  3. Gromova, O.A. , Torshin, I.Y., Limanova, O.A. “Prospects for the use of myo-inositol in women with polycystic ovaries and insulin resistance in pregravid preparation programs for in vitro fertilization.” Effective pharmacotherapy. Obstetrics and gynecology 5.51 (2013): 58–65.
  4. Dicke, G.B. “Vitamin and mineral complex for pregnant women: modern formula.” Pharmateca 6 (2021): 100–7.
  5. Zhabchenko, I.A., Siudmak, О.Р. “Problems of delayed childbirth: features of fertility in older women and methods of their correction.” Reproductive endocrinology 5 (2019): 47–53.
  6. Zhabchenko, I.A. “Modern view on the role of folate in the prevention of perinatal problems.” Reproductive endocrinology 2.46 (2019): 57–61.
  7. Zaichenko, A.V. “Folates and omega-3-PUFAs in obstetrics: more than prevention of neural tube defects.” Health of Ukraine. Gynecology. Obstetrics. Reproductology 1 (2018): 1–4.
  8. Kalacheva, A.G., Torshin, I.Y., Stelmashuk, E.V., et al. “Neuroprotective effect of myo-inositol on a cellular model of glutamate stress as a basis for the prevention of intrauterine brain development disorders.” Pharmacokinetics and Pharmacodynamics 3 (2018): 9–20.
  9. Kalugina, L.V., Yusko, T.I. “Myo-inositol: Therapeutic possibilities and pregravid preparation in polycystic ovary syndrome.” Reproductive endocrinology 4.42 (2018): 40–5.
  10. Kareva, E.N., Zorina, L.A., Sudnitsyna, M.V. “Tetrahydrofolate: role in pregravid preparation and pregnancy management.” Obstetrics and Gynecology: News, Opinions, Training 7.2 (2019): 59–63.
  11. Kulyutsina, E.R., Tatarchenko, I.P., Levashova, O.A., et al. “Interrelation of homocysteine indices and genetic polymorphisms causing folate metabolism disorders in healthy population.” Clinical laboratory diagnostics 2 (2017): 82–7.
  12. Limanova, O.A., Gromova, O.A., Torshin, I.Y., et al. “Systematic analysis of the molecular physiological effects of myo-inositol: data from molecular biology, experimental and clinical medicine.” Effective pharmacotherapy 28 (2013): 32–41.
  13. Mishchenko, V.P., Rudenko, I.V., Zaporozhchenko, M.B., et al. “Peculiarities of pre-pregnancy training of women of different nationalities.” Current issues of pediatrics, obstetrics and gynecology 1.19 ( 2017): 105–10.
  14. Mikhailyukova, V.A. “Ideal folate: myth or reality?” Gynecology 8.19 (2020): 55–60.
  15. Pustotina, O.A., Akhmedova, A.E. “The role of folates in the development of pregnancy complications.” Women's health 1.117 (2017): 56–61.
  16. Rudenko, I.V., Mishchenko, V.P. “Pathogenetic substantiation of personified correction of folate cycle disorders using a complex with metafolin for the prevention of congenital malformations.” Reproductive endocrinology 2 (2020): 67–71.
  17. Tatarchuk, T.F. “The main aspects of women's reproductive health: vitamin D.” Health of Ukraine 3.31 (2018): 13–4.
  18. Tatarchuk, T.F., Ganzhyi, I.Y., Педаченко, N.Y., Kapshuk, І.М. “Modern possibilities of non-hormonal treatment of polycystic ovary syndrome in obese women.” Reproductive endocrinology 5.13 (2013): 19–21.
  19. Torshin, I.Y., Gromova, O.A., Kalacheva, A.G., et al. “Myo-inositol: a micronutrient for “fine tuning” the female reproductive sphere.” Russian Journal of Woman and Child Health 2.1 (2018): 148–55.
  20. Khilkevich, E.G., Yazykova, O.I. “Active folates with 100% assimilation.” Medical Council 2 (2017): 48–50.
  21. Khmil, M.S., Khmil-Doswald, A.S., Khmil, S.V., Pidhaina, I.Y. “Prospects for the use of inositol in women with polycystic ovary syndrome (literature review).” Bulletin of social hygiene and health care organization of Ukraine 4.78 (2018): 82–9.
  22. Chernukha, G.E., Udovichenko, М.А. , Naidukova, А.А. “Mechanisms of formation of insulin resistance in polycystic ovary syndrome and therapeutic effects of myo-inositol.” Gynecology 11.166 (2019): 55–60.
  23. Shapoval, O.S., Reznichenko, G.I. “Features of the implementation of reproductive function in women with benign tumor-like formations of the ovaries.” Women's health 2.98 (2014): 104–7.
  24. Shikh, E.V., Makhova, A.A. “Advantages of correcting folate status using a vitamin-mineral complex containing metafoline.” Difficult patient 8–9 (2013): 26–31.
  25. Ahmed, T., Fellus, I., Gaudet, J., et al. “Effect of folic acid on human trophoblast health and function in vitro.” Placenta 2016, 37: 7–15.
  26. Calogero, A.E., et al. “Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebocontrolled study.” Andrology 3 (2015): 491–5.
  27. Chitayat, D., Matsui, D., Amitai, Y., et al. “Folic Acid Supplementation for Pregnant Women and Those Planning Pregnancy: 2015 Update.” J Clin Pharmacol 56.2 (2016): 170–5.
  28. Emekçi Özay, Ö., Özay, A.C., Çağlıyan, E., et al. “Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial.” Gynecol Endocrinol 33.7 (2017): 524–8.
  29. Facchinetti, F., Orrù, B., Grandi, G., Unfer, V. “Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials.” Gynecol Endocrinol 7 (2019): 1–9.
  30. Garg, D., Tal, R. “Inositol treatment and art outcomes in women with PCOS.” Int J Endocrinol 2016: 1979654.
  31. Gaskins, A.J., Chiu, Y., Williams, P.L., et al. “Association between serum folate and vitamin B-12 and outcomes of assisted reproductive technologies.” Am J Clin Nutr 102.1 (2015): 943–50.
  32. Genazzani, A. “Inositol as putative integrative treatment for PCOS.” Reproductive BioMedicine Online 33.6 (2016): 770–80.
  33. FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. “Good clinical practice advice: Micronutrients in the periconceptional period and pregnancy.” Obstet Gynecol 44.3 (2019): 317–21.
  34. Gong, R., Wang, Z.P., Wang, M., et al. “The Effects of Preconception Examinations on Neural Tube Defects and the Primary Preventive Measures: Case-control Study.” J Matern Fetal Neonatal Med 29.17 (2016): 2773–9.
  35. Greene, N.D., et al. “Inositol for the prevention of neural tube defects: a pilot randomised controlled trial.” Br J Nutr 115.6 (2016): 974–83.
  36. Jahanbin, A., et al. “Folic Acid Supplementation and the Risk of Oral Clefts in Offspring.” J Craniofac Surg 29.6 (2018): e534–41.
  37. Keats, E.C., Haider, B.A., Tam, E., Bhutta, Z.A. “Multiple-micronutrient supplementation for women during pregnancy.” Cochrane Database Syst Rev 3 (2019): CD004905.
  38. Laganà, A.S., Garzon, S., Casarin, J., et al. “Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach.” Trends Endocrinol Metab 29.11 (2018): 768–80.
  39. Laganà, A.S., Vitale, S.G., Noventa, M., Vitagliano, A. “Current management of polycystic ovary syndrome: from bench to bedside.” Int J Endocrinol (2018): 7234543.
  40. Le Donne, M., Metro, D., Alibrandi, A., et al. “Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome.” Eur Rev Med Pharmacol Sci 23.5 (2019): 2293–2301.
  41. Li, B., Zhang, X., Peng, X., et al. “Folic Acid and Risk of Preterm Birth: A Meta-Analysis.” Front Neurosci 13 (2019): 1284.
  42. Liu, C., Liu, C., Wang, Q., Zhang, Z. “Supplementation of folic acid in pregnancy and the risk of preeclampsia and gestational hypertension: a meta-analysis.” Arch Gynecol Obstet 298.4 (2018): 697–704.
  43. Mann, J.S., Lowther, K.M., Mehlmann, L.M. “Reorganization of the endoplasmic reticulum and development of Ca2+ release mechanisms during meiotic maturation of human oocytes.” Biol Reprod 83.4 (2010): 578–83.
  44. Martinussen, M.P., Bracken, M.B., Triche, E.W., et al. “Folic acid supplementation in early pregnancy and the risk of preeclampsia, small for gestational age offspring and preterm delivery.” Eur J Obstet Gynecol Reprod Biol 195 (2015): 94–9.
  45. Milewska, E.M., Czyzyk, A., Meczekalski, B., Genazzani, A.D. “Inositol and human reproduction: from cellular metabolism to clinical use.” Gynecol Endocrinol 32.9 (2016): 690–5.
  46. Mousa, A., Naqash, A., Lim, S. “Macronutrient and Micronutrient Intake during Pregnancy: An Overview of Recent Evidence.” Nutrients 11.2 (2019): 443.
  47. Oh, C., Keats, E.C., Bhutta, Z.A. “Vitamin and Mineral Supplementation During Pregnancy on Maternal, Birth, Child Health and Development Outcomes in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.” Nutrients 12.2 (2020): 491.
  48. Pundir, J., Psaroudakis, D., Savnur, P., et al. “Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.” BJOG 125.3 (2018): 385–6.
  49. Regidor, P.A., Schindler, A.E., Lesoine, B., Druckman, R. “Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature.” Horm Mol Biol Clin Investig 34.2 (2018).
  50. Simi, G., Genazzani, A.R., Obino, M.E., et al. “Inositol and in vitro fertilization with embryo transfer.” Int J Endocrinol 2017 (2017): 5469409.
  51. Singh, M.D., Thomas, P., Owens, J., et al. “Potential role of folate in pre-eclampsia.” Nutr Rev 73.10 (2015): 694–722.
  52. Teede, H.J., Misso, M.L., Costello, M.F., et al. “Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.” Fertil Steril 110.3 (2018): 364–79.
  53. Unfer, V., Facchinetti, F., Orrù, B., et al. “Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials.” Endocrine Connections 6 (2017): 647–58.
  54. Vartanyan, E.V., Tsaturova, K.A., Devyatova, E.A., et al. “Improvement in quality of oocytes in polycystic ovarian syndrome in programs of in vitro fertilization.” Gynecol Endocrinol 33.1 (2017): 8–11.
  55. Walecki, J., Barcikowska, M., Cwikla, J.B., Gabryelewicz, T. “N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI).” Med Sci Monit 17.12 (2011): MT105–11.
  56. Wallingford, J.B., Niswander, L.A., Shaw, G.M., Finnell, R.H. “The continuing challenge of understanding, preventing, and treating neural tube defects.” Science 339.6123 (2013): 1222002.
  57. Wang, Y., Cao, Z., Peng, Z., et al. “Folic acid supplementation, preconception body mass index, and preterm delivery: findings from the preconception cohort data in a Chinese rural population.” BMC Pregnancy Childbirth 15.9 (2015): 336.
  58. World Health Organization. “WHO antenatal care recommendations for a positive pregnancy experience. Nutritional interventions update: Multiple micronutrient supplements during pregnancy.” Geneva: WHO (2020): 172 р.
  59. Wilson, R.L., Gummow, J.A., McAninch, D., et al. “Micronutrient supplementation in pregnancy.” J Pharm Pract Res 48 (2018): 186–92.
  60. Zheng, X., Lin, D., Zhang, Y., et al. “Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET.” Medicine (Baltimore) 96.49 (2017): e8842.



How to Cite

Reznichenko, H., & Reznichenko, Y. (2021). Inositol and folates in the restoration of reproductive function in women and prevention of congenital malformations: Literature review . REPRODUCTIVE ENDOCRINOLOGY, (61), 95–100.



Drug therapy